Global Breast Cancer Monoclonal Antibodies Market 2016-2020
About Breast Cancer mAbs
Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell.
Technavio’s analysts forecast the global breast cancer monoclonal antibodies (mAbs) market to post a revenue of 13.7 billion by 2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global breast cancer monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of branded mAbs and biosimilars used to treat breast cancer.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020
Technavio recognizes the following companies as the key players in the global breast cancer monoclonal antibodies (mAbs) market: Roche, Amgen, and Mylan.
Other Prominent Vendors in the market are: Actavis, Array BioPharma, AstraZeneca, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celldex Therapeutics, Celltrion, Chugai Pharmaceutical, Daiichi Sankyo, DARA Biosciences, Eddingpharm, Eisai, Galena Biopharma, GlaxoSmithKline, Halozyme Therapeutics, Hospira, ImmunoGen, Immunomedics, MacroGenics, Merck, Novartis, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Seattle Genetics, Sun Pharmaceutical Industriesf, Synta Pharmaceuticals, and Teva Pharmaceuticals.
Commenting on the report, an analyst from Technavio’s team said: “Huge funds are required for a company to enter the global breast cancer mAbs market and invest in the R&D and manufacturing processes related to the same. Vendors have identified mAb products as a significant long-term growth opportunity. The pharmaceutical industry is a research-intensive industry backed by developments in technology. The vendors in this market are allocating huge R&D budgets to enable the introduction of a broad portfolio of mAbs. This would help increase the market penetration of the vendors in the global market to a great extent. Thus, the huge investment in the R&D of mAbs is another trend witnessed by the global breast cancer mAbs market, influencing market growth.”
According to the report, exposure to risk factors will be a key driver for market growth. Exposure to risk factors for breast cancer and the decrease in practices that reduce this risk are expected to increase the incidence of breast cancer. The disease is associated with modifiable risk factors such as physical inactivity, alcohol consumption, obesity, and weight gain. For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer. Oral contraceptives and postmenopausal estrogen-progestogen hormone replacement therapy increase the risk of the developing the disease because they contain synthetic sex hormones. Overweight postmenopausal women have elevated estrogen levels because they have more estrogen-producing fatty tissue. These levels increase the likelihood of developing the disease. Physical activity helps lower estrogen levels, and thus negates the risk factors. Breastfeeding is also known to protect women against breast cancer.
Further, the report states that the number of patients available for clinical studies is less, making it difficult to generate significant comparative data. This is a major challenge in conducting clinical studies and for the market. The participation of sites across multiple geographies is required, but only very few patients are enrolled at each site. This may lead to delays in the recruitment process, which can add to the cost and uncertainty of the program. Pharmaceutical companies developing mAbs conduct clinical trials on a limited patient population. This requires efforts to mitigate the higher risk of uncertainty associated with the use of these drugs and accelerates approval procedures. The US FDA mandates manufacturers to satisfy Risk Evaluation and Mitigation Strategy (REMS) programs that include elements to ensure safe use before and after approval. The assessment of safety labels during clinical trials becomes difficult because of the limited availability of premarket data for the evaluation of mAbs and the smaller patient population.
Roche, Amgen, Mylan, Actavis, Array BioPharma, AstraZeneca, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celldex Therapeutics, Celltrion, Chugai Pharmaceutical, Daiichi Sankyo, DARA Biosciences, Eddingpharm, Eisai, Galena Biopharma, GlaxoSmithKline, Halozyme Therapeutics, Hospira, ImmunoGen, Immunomedics, MacroGenics, Merck, Novartis, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Seattle Genetics, Sun Pharmaceutical Industriesf, Synta Pharmaceuticals, Teva Pharmaceuticals.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook